The company is using its informatics services business to inform internal diagnostic research and development efforts.
The firm said that the RealTime CMV test is the only commercially available cytomegalovirus that can amplify two select regions of the CMV genome.
The kit was previously approved by FDA for use on Qiagen's Rotor-Gene Q real-time PCR platform, which is one component of the automated QiaSymphony platform.
It is the first FDA-approved test for the stem cell transplant use case and meets the WHO International Standard for comparable results.
Following a beta evaluation of the system, a virology lab in Sheffield, UK, ran a workflow assessment and found improvements with the system.
The DxN Veris was recently launched as a CE-marked product with a menu of viral load tests, and will launch in a few years in the US with STD and HAI assays.
In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.
A team of researchers has characterized the genomic diversity of the human cytomegalovirus and uncovered potential therapeutic targets.
The German firm has signed a deal for BL&H to distribute, market, and sell its T-Track CMV kit in South Korea once it is approved as an in vitro diagnostic.
The firm is pursuing CE-IVD clearance of the new platform populated with a menu of its MGB assays.
An opinion piece at Bloomberg discusses China's stance on genomic research.
Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.
Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.
In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.